-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: interpretation
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for ulcerative colitis
Byron P Vaughn, Alan C Moss
Review: Clinical Trail Outcomes: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation
-
Chloroquine enjoys a renaissance as an antineoplastic therapy
Virginia Espina, Lance A Liotta
Therapeutic Prospective: Clinical Investigation